

Award Number:  
W81XWH-10-2-0133

TITLE:  
Treatment of Early Post-op Wound Infection after Internal Fixation

PRINCIPAL INVESTIGATOR:  
William Obremskey, M.D.

CONTRACTING ORGANIZATION:  
Vanderbilt University Medical Center  
Nashville TN 37203

REPORT DATE:  
October 2015

TYPE OF REPORT:  
Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:

x Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
*OMB No. 0704-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> October 2015		<b>2. REPORT TYPE</b> Annual		<b>3. DATES COVERED (From - To)</b> 15Sep2014 - 14Sep2015	
<b>4. TITLE AND SUBTITLE</b> Treatment of Early Post-Op Wound Infection after Internal Fixation				<b>5a. CONTRACT NUMBER</b> W81XWH-10-2-0133	
				<b>5b. GRANT NUMBER</b> W81XWH-10-2-0133	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> William Obremskey, Principal Investigator  email: william.obremskey@vanderbilt.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Vanderbilt University Medical Center 3319 West End Ave, Suite 100 Nashville TN 37203				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Severe fractures are common in modern warfare with fractures being fixed via internal fixation of plates and screws to hold the fracture stable while the bone heals. Approximately 10%-40% of severe fractures fixed with internal fixation develop a deep wound infection during the healing process. Thus, the overall goals of this study are to (1) evaluate the effect of treatment of post-op wound infection in long bones after fracture fixation or joint fusion and either: (Group 1) operative debridement and PO antibiotic treatment for 6 weeks; or (Group 2) operative debridement and IV antibiotics for 6 weeks and (2) build and validate a risk prediction model for failure of treatment of early postoperative wound infections after fixation of fractures or joint fusion.					
<b>15. SUBJECT TERMS</b> Nothing Listed					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  UU	<b>18. NUMBER OF PAGES</b>  5	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER (include area code)</b>

### Table of Contents

	<u>Page</u>
Introduction.....	5
<b>Body.....</b>	<b>5</b>
<b>Key Research Accomplishments.....</b>	<b>5</b>
<b>Reportable Outcomes.....</b>	<b>5</b>
<b>Conclusion.....</b>	<b>5</b>
<b>References.....</b>	<b>5</b>
<b>Appendices.....</b>	<b>5</b>

**Annual Report: “Treatment of Early Post-Op Wound Infection after Internal Fixation”  
Sept. 15, 2014 - Sept. 14, 2015**

**Introduction:**

Severe fractures are common in modern warfare with fractures being fixed via internal fixation of plates and screws to hold the fracture stable while the bone heals. Approximately 10%-40% of severe fractures fixed with internal fixation develop a deep wound infection during the healing process. Thus, the overall goals of this study are to (1) evaluate the effect of treatment of post-op wound infection in long bones after fracture fixation or joint fusion and either: (Group 1) operative debridement and PO antibiotic treatment for 6 weeks; or (Group 2) operative debridement and IV antibiotics for 6 weeks and (2) build and validate a risk prediction model for failure of treatment of early postoperative wound infections after fixation of fractures or joint fusion.

**Body:**

During the current reporting period, the Principal Investigator (PI) focused on administrative tasks essential to recruitment and enrollment into the study. As of October 1, 2015, a total of 634 patients have been screened for eligibility, and of these, 258 (41%) were eligible. Initial screening criteria for POvIV are all patients, age 18-84, inclusive, with long bone fractures or joint fusions, AND suspected to have a wound infection pending intra-operative cultures. Of the 258 eligible patients, 120 were enrolled in the study. Of the 120 patients enrolled, 88 were enrolled into the RCT and 32 were enrolled into the observational study. We have now reached 33.3% of our total enrollment. Twenty-six patients have completed the study.

Due to a lapse in cellular service and some difficulties working with Vitality, we decided to make the transition to using a different apparatus to monitor patient oral medication adherence. We are moving from using the Vitality GlowCaps to a different apparatus called the Medication Event Monitoring System (MEMS). With an electronic cap which automatically compiles drug dosing history in a web based system we be able to track medication adherence in a similar fashion as we did with the GlowCaps. The amendment including this adherence tracking change has been approved by the Johns Hopkins School of Public Health IRB and has been distributed to all the sites.

Task 1	Months 1-6	Completed
Task 2	Months 2-6	Completed
Task 3	Months 7-30	Roll out of enrollment – in progress
Task 4	Months 7-42	Enrollment ongoing
Task 5	Months 43-48	initiated

**NEXT STEPS:**

- Assist sites with facilitation of the approval of the amendment that changes our adherence technology to the MEMS cap.
- Train on coordinators on the use of the MEMS cap.
- Provide follow up support and guidance to the sites during implementation of the MEMS caps
- Encourage sites to schedule meetings Infectious Disease teams to review study and study roles
- Develop Reports related to project deliverables for Consortium

**Key Research Accomplishments:**

- We have completed over 33% of our enrollment goals
- Twenty-six patients have completed the study
- The implementation of the observation arm has increased our enrollment rate.

**Reportable Outcomes:**

There were 5 serious adverse events (SAEs) reported during this reporting period. All five events were related to abnormal laboratory results and each determined by the medical monitor to be unrelated to study participation.

**Conclusion:**

None

**References:**

None

**Appendices:**

None